1589 related articles for article (PubMed ID: 15520361)
21. Effects of D-cycloserine on extinction of learned fear to an olfactory cue.
Weber M; Hart J; Richardson R
Neurobiol Learn Mem; 2007 May; 87(4):476-82. PubMed ID: 17275356
[TBL] [Abstract][Full Text] [Related]
22. Learning and memory in conditioned fear extinction: effects of D-cycloserine.
Vervliet B
Acta Psychol (Amst); 2008 Mar; 127(3):601-13. PubMed ID: 17707326
[TBL] [Abstract][Full Text] [Related]
23. D-cycloserine enhances generalization of fear extinction in children.
Byrne SP; Rapee RM; Richardson R; Malhi GS; Jones M; Hudson JL
Depress Anxiety; 2015 Jun; 32(6):408-14. PubMed ID: 25775435
[TBL] [Abstract][Full Text] [Related]
24. Augmentation of cognitive behavioral therapy with pharmacotherapy.
Ganasen KA; Ipser JC; Stein DJ
Psychiatr Clin North Am; 2010 Sep; 33(3):687-99. PubMed ID: 20599140
[TBL] [Abstract][Full Text] [Related]
25. Social phobia. Longitudinal course and long-term outcome of cognitive-behavioral treatment.
Juster HR; Heimberg RG
Psychiatr Clin North Am; 1995 Dec; 18(4):821-42. PubMed ID: 8748383
[TBL] [Abstract][Full Text] [Related]
26. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.
Heresco-Levy U; Javitt DC; Gelfin Y; Gorelik E; Bar M; Blanaru M; Kremer I
J Affect Disord; 2006 Jul; 93(1-3):239-43. PubMed ID: 16677714
[TBL] [Abstract][Full Text] [Related]
27. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications.
Richardson R; Ledgerwood L; Cranney J
Learn Mem; 2004; 11(5):510-6. PubMed ID: 15466301
[TBL] [Abstract][Full Text] [Related]
28. A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder.
de Kleine RA; Hendriks GJ; Kusters WJ; Broekman TG; van Minnen A
Biol Psychiatry; 2012 Jun; 71(11):962-8. PubMed ID: 22480663
[TBL] [Abstract][Full Text] [Related]
29. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats.
Parnas AS; Weber M; Richardson R
Neurobiol Learn Mem; 2005 May; 83(3):224-31. PubMed ID: 15820858
[TBL] [Abstract][Full Text] [Related]
30. The use of virtual reality in acrophobia research and treatment.
Coelho CM; Waters AM; Hine TJ; Wallis G
J Anxiety Disord; 2009 Jun; 23(5):563-74. PubMed ID: 19282142
[TBL] [Abstract][Full Text] [Related]
31. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.
Farrell LJ; Waters AM; Boschen MJ; Hattingh L; McConnell H; Milliner EL; Collings N; Zimmer-Gembeck M; Shelton D; Ollendick TH; Testa C; Storch EA
Depress Anxiety; 2013 Aug; 30(8):723-31. PubMed ID: 23722990
[TBL] [Abstract][Full Text] [Related]
32. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia.
Smits JA; Rosenfield D; Otto MW; Powers MB; Hofmann SG; Telch MJ; Pollack MH; Tart CD
Biol Psychiatry; 2013 Jun; 73(11):1054-8. PubMed ID: 23332511
[TBL] [Abstract][Full Text] [Related]
33. Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flying.
Rothbaum BO; Anderson P; Zimand E; Hodges L; Lang D; Wilson J
Behav Ther; 2006 Mar; 37(1):80-90. PubMed ID: 16942963
[TBL] [Abstract][Full Text] [Related]
34. D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.
Difede J; Cukor J; Wyka K; Olden M; Hoffman H; Lee FS; Altemus M
Neuropsychopharmacology; 2014 Apr; 39(5):1052-8. PubMed ID: 24217129
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects.
Watson BJ; Wilson S; Griffin L; Kalk NJ; Taylor LG; Munafò MR; Lingford-Hughes AR; Nutt DJ
Psychopharmacology (Berl); 2011 Jul; 216(1):121-9. PubMed ID: 21318564
[TBL] [Abstract][Full Text] [Related]
36. Extinction retention predicts improvement in social anxiety symptoms following exposure therapy.
Berry AC; Rosenfield D; Smits JA
Depress Anxiety; 2009; 26(1):22-7. PubMed ID: 18781661
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
38. Glucocorticoids enhance in vivo exposure-based therapy of spider phobia.
Soravia LM; Heinrichs M; Winzeler L; Fisler M; Schmitt W; Horn H; Dierks T; Strik W; Hofmann SG; de Quervain DJ
Depress Anxiety; 2014 May; 31(5):429-35. PubMed ID: 24265104
[TBL] [Abstract][Full Text] [Related]
39. D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction.
Ledgerwood L; Richardson R; Cranney J
Biol Psychiatry; 2005 Apr; 57(8):841-7. PubMed ID: 15820704
[TBL] [Abstract][Full Text] [Related]
40. Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale.
Hofmann SG; Carpenter JK; Otto MW; Rosenfield D; Smits JA; Pollack MH
Contemp Clin Trials; 2015 Jul; 43():223-30. PubMed ID: 26111923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
